Table 1.
Descriptive statistics of variables in data set by adverse event for 471 patients with percutaneous coronary intervention
|
No MACE (n = 324)
|
Had MACE (n = 147)
|
|||||
|
n
|
mean
|
SD
|
n
|
mean
|
SD
|
|
| Systolic SD | 324 | 13.72 | 6.02 | 147 | 15.38 | 5.26 |
| Diastolic SD | 324 | 8.54 | 3.11 | 147 | 8.93 | 2.71 |
| Systolic LC | 324 | 37.11 | 14.79 | 147 | 44.31 | 15.42 |
| Diastolic LC | 324 | 23.60 | 7.78 | 147 | 26.37 | 9.09 |
| Systolic average | 324 | 131.83 | 11.47 | 147 | 132.20 | 11.63 |
| Diastolic average | 324 | 74.82 | 7.75 | 147 | 71.33 | 7.64 |
| Number of BP readings | 324 | 40.19 | 35.86 | 147 | 62.81 | 52.85 |
| Mean days between readings | 324 | 59.07 | 37.04 | 147 | 42.19 | 30.70 |
| Age | 322 | 67.87 | 11.21 | 147 | 70.69 | 11.86 |
| Pre PCI LVEF | 252 | 56.44 | 11.73 | 122 | 53.06 | 13.63 |
| Pre creatinine | 307 | 1.15 | 0.98 | 138 | 1.50 | 1.19 |
| n | % | n | % | |||
| Sex | 469 | |||||
| Male | 110 | 74.83 | 228 | 70.37 | ||
| Female | 37 | 25.17 | 94 | 29.01 | ||
| Race | 469 | |||||
| White | 142 | 96.60 | 312 | 96.30 | ||
| Other | 5 | 3.40 | 10 | 3.09 | ||
| Hispanic | 1 | 0.68 | 4 | 1.23 | ||
| Smokes | 467 | 22 | 14.97 | 51 | 15.74 | |
| Has hypertension | 469 | 135 | 91.84 | 266 | 82.10 | |
| Has diabetes | 469 | 67 | 45.58 | 122 | 37.65 | |
| Had prior CVD | 469 | 39 | 26.53 | 68 | 20.99 | |
| Had prior MI | 470 | 106 | 32.72 | 63 | 42.86 | |
| Had prior PCI | 470 | 125 | 38.58 | 67 | 45.58 | |
| Had prior CABG | 470 | 53 | 16.36 | 41 | 27.89 | |
| Prior creatinine | 445 | |||||
| 0 to 2 | 296 | 91.36 | 118 | 80.27 | ||
| > 2 to 5 | 8 | 2.47 | 18 | 12.24 | ||
| > 5 | 3 | 0.93 | 2 | 1.36 | ||
| Anginal class | 469 | |||||
| No symptoms | 33 | 22.45 | 24 | 7.41 | ||
| CCS I | 11 | 7.48 | 39 | 12.04 | ||
| CCS II | 27 | 18.37 | 87 | 26.85 | ||
| CCS III | 43 | 29.25 | 95 | 29.32 | ||
| CCS IV | 33 | 22.45 | 77 | 23.77 | ||
| On anti-anginal medication | 469 | 114 | 77.55 | 204 | 62.96 | |
| Beta-blockers | 98 | 66.67 | 164 | 50.62 | ||
| Calcium channel blockers | 37 | 25.17 | 76 | 23.46 | ||
| Long-acting nitrates | 33 | 22.45 | 41 | 12.65 | ||
| Ranolazine | 3 | 2.04 | 2 | 0.62 | ||
| Indication | 471 | |||||
| Non-STEMI | 82 | 55.78 | 167 | 51.54 | ||
| STEMI | 9 | 6.12 | 39 | 12.04 | ||
| Other stage | 56 | 38.10 | 118 | 36.42 | ||
| MACE within 1 yr | 471 | |||||
| Readmission | 131 | 27.81 | ||||
| MI | 47 | 9.98 | ||||
| Death | 21 | 4.46 | ||||
| CVA | 6 | 1.27 | ||||
MACE: Major adverse cardiac events; SD: Standard deviation; LC: Largest change; BP: Blood pressure; PCI: Percutaneous coronary intervention; LVEF: Left ventricular ejection fraction; CVD: Cardiovascular disease; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass graft; CCS: Canadian Cardiovascular Society; STEMI: ST-segment elevation myocardial infarction; CVA: Cerebrovascular accident.